ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 9, 2016, Pages 2405-2413

  Maschmeyer, Georg ^a,h   Helweg Larsen, Jannik ^b   Pagano, Livio ^c   Robin, Christine ^d,e,h   Cordonnier, Catherine ^d,e,h   Schellongowski, Peter ^f,g,h   Akova, Murat ^h   Aljurf, Mahmoud ^h   Averbuch, Dina ^h   Barnes, Rosemary ^h   Blennow, Ola ^h   Bochud, Pierre Yves ^h   Bouza, Emilio ^h   Bretagne, Stéphane ^h   Brüggemann, Roger ^h   Calandra, Thierry ^h   Carratalà, Jordi ^h   Cesaro, Simone ^h   Cornely, Oliver ^h   Dalianis, Tina ^h   De La Camara, Rafael ^h   Donnelly, Peter ^h   Drgona, Lubos ^h   Duarte, Rafael ^h   Einsele, Hermann ^h   Engelhard, Dan ^h   Fox, Christopher ^h   Girmenia, Corrado ^h   Groll, Andreas ^h   Heldal, Dag ^h   Helweg Larsen, Jannick ^h   Herbrecht, Raoul ^h   Hirsch, Hans ^h   Johnson, Elisabeth ^h   Klyasova, Galina ^h   Koskuenvo, Minna ^h   Lagrou, Katrien ^h   Lewis, Russell E ^h   Ljungman, Per ^h   Maertens, Johan ^h   Mikulska, Malgorzata ^h   Nucci, Marcio ^h   Padoin, Christophe ^h   Dwe, A L L W ^h   Pagliuca, Antonio ^h   Racil, Zdenek ^h   Ribaud, Patricia ^h   Rinaldo, Christine ^h   Rizzi Puechal, Valérie ^h   Roilides, Emmanuel ^h   Rovira, Montserrat ^h   Rupp, Markus ^h   Sanchez, Sonia ^h   Sedlacek, Peter ^h   Sinko, Janos ^h   Slavin, Monica ^h   Ferreira, Isabella Sousa ^h   Styczynski, Jan ^h   Tissot, Frederic ^h   Viscoli, Claudio ^h   Ward, Katherine ^h   Witschi, Anne Therese ^h   more..

^a KLINIKUM ERNST VON BERGMANN   (Germany)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c CATHOLIC UNIVERSITY   (Italy)

^d HENRI MONDOR HOSPITAL   (France)

^e UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g Intensive Care in Hematologic and Oncologic Patients

^h NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; CLINDAMYCIN; COTRIMOXAZOLE; PRIMAQUINE;

COMPLICATION; DRUG EFFECTS; HEMATOLOGIC DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PNEUMOCYSTIS CARINII; PNEUMONIA, PNEUMOCYSTIS; PRACTICE GUIDELINE;

ADMINISTRATION, INTRAVENOUS; ANTIFUNGAL AGENTS; CLINDAMYCIN; HEMATOLOGIC NEOPLASMS; HUMANS; PNEUMOCYSTIS CARINII; PNEUMONIA, PNEUMOCYSTIS; PRIMAQUINE; TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION;

EID: 85021787375     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw158     Document Type: Article

References (82)

1. Hughes WT, Feldman S, Aur RJ et al. Intensity of immunosuppressive therapy and the incidence of Pneumocystis carinii pneumonitis. Cancer 1975; 36: 2004-9.
2. Kojicic M, Li G, Hanson AC, Lee KM et al. Risk factors for the development of acute lung injury in patients with infectious pneumonia. Crit Care 2012; 16: R46.
3. Morris AM, Huang L, Bacchetti P et al. Permanent declines in pulmonary function following pneumonia in human immunodeficiency virus-infected persons. The Pulmonary Complications of HIV Infection Study Group. Am J Respir Crit Care Med 2000; 162: 612-6.
4. ZolopaA, Andersen J, PowderlyWet al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One 2009; 4: e5575.
5. Alanio A, Hauser PM, Lagrou K et al. ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother 2016; 71: 2386-96.
6. Cordonnier C, Cesaro S, Maschmeyer G et al. Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother 2016; 71: 2379-85.
7. Maertens J, Cesaro S, Maschmeyer G et al. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother 2016; 71: 2397-404.
8. Ullmann AJ, Akova M, Herbrecht R et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect 2012; 18 Suppl 7: 53-67.
9. Pagano L, Fianchi L, Mele L et al. Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centres. Br J Haematol 2002; 117: 379-86.
10. Bolleé G, Sarfati C, Thiéry G et al. Clinical picture of Pneumocystis jiroveci pneumonia in cancer patients. Chest 2007; 132: 1305-10.
11. Ewig S, Bauer T, Schneider C et al. Clinical characteristics and outcome of Pneumocystis carinii pneumonia in HIV-infected and otherwise immunosuppressed patients. Eur Respir J 1995; 8: 1548-53.
12. Toper C, Rivaud E, Daniel C et al. [Pneumocystis jirovecii pneumonia in non-HIV infected patients: a study of 41 cases]. Rev Pneumol Clin 2011; 67: 191-8.
13. Torres HA, Chemaly RF, Storey R et al. Influence of type of cancer and hematopoietic stem cell transplantation on clinical presentation of Pneumocystis jiroveci pneumonia in cancer patients. Eur J Clin Microbiol Infect Dis 2006; 25: 382-8.
14. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc 1996; 71: 5-13.
15. Asai N, Motojima S, Ohkuni Y et al. Early diagnosis and treatment are crucial for the survival of Pneumocystis pneumonia patients without human immunodeficiency virus infection. J Infect Chemother 2012; 18: 898-905.
16. Guo F, Chen Y, Yang SL et al. Pneumocystis pneumonia in HIV-infected and immunocompromised non-HIV infected patients: a retrospective study of two centers in China. PLoS One 2014; 9: e101943.
17. Li MC, Lee NY, Lee CC et al. Pneumocystis jiroveci pneumonia in immunocompromised patients: delayed diagnosis and poor outcomes in non-HIV-infected individuals. J Microbiol Immunol Infect 2014; 47: 42-7.
18. Roux A, Canet E, Valade S et al. Pneumocystis jirovecii pneumonia in patients with or without AIDS, France. Emerg Infect Dis 2014; 20: 1490-7.
19. Roger PM, Vandenbos F, Pugliese P et al. Persistence of Pneumocystis carinii after effective treatment of P. carinii pneumonia is not related to relapse or survival among patients infected with human immunodeficiency virus. Clin Infect Dis 1998; 26: 509-10.
20. Roux A, Gonzalez F, Roux M et al. Update on pulmonary Pneumocystis jirovecii infection in non-HIV patients. Med Mal Infect 2014; 44: 185-98.
21. Miller RF, Le Noury J, Corbett EL et al. Pneumocystis carinii infection: current treatment and prevention. J Antimicrob Chemother 1996; 37 Suppl B: 33-53.
22. Asai N, Motojima S, Ohkuni Y et al. Non-HIV Pneumocystis pneumonia: do conventional community-acquired pneumonia guidelines under estimate its severity? Multidiscip Respir Med 2012; 7: 2.
23. Boonsarngsuk V, Sirilak S, Kiatboonsri S. Acute respiratory failure due to Pneumocystis pneumonia: outcome and prognostic factors. Int J Infect Dis 2009; 13: 59-66.
24. Cerón I, Rabagliati R, Langhaus J et al. [Pneumocystis jiroveci pneumonia: comparative study of cases in HIV-infected patients and immunocompromised non-HIV-infected patients]. Rev Chilena Infectol 2014; 31: 417-24.
25. Kim SJ, Lee J, Cho YJ et al. Prognostic factors of Pneumocystis jirovecii pneumonia in patients without HIV infection. J Infect 2014; 69: 88-95.
26. Kofteridis DP, Valachis A, Velegraki M et al. Predisposing factors, clinical characteristics and outcome of Pneumocystis jirovecii pneumonia in HIV-negative patients. J Infect Chemother 2014; 20: 412-6.
27. Moon SM, Kim T, Sung H et al. Outcomes of moderate-to-severe Pneumocystis pneumonia treated with adjunctive steroid in non-HIV-infected patients. Antimicrob Agents Chemother 2011; 55: 4613-8.
28. Ko Y, Jeong BH, Park HY et al. Outcomes of Pneumocystis pneumonia with respiratory failure in HIV-negative patients. J Crit Care 2014; 29: 356-61.
29. Matsumura Y, Shindo Y, Iinuma Y et al. Clinical characteristics of Pneumocystis pneumonia in non-HIV patients and prognostic factors including microbiological genotypes. BMC Infect Dis 2011; 11: 76.
30. McKinnell JA, Cannella AP, Kunz DF et al. Pneumocystis pneumonia in hospitalized patients: a detailed examination of symptoms, management, and outcomes in human immunodeficiency virus (HIV)-infected and HIV-uninfected persons. Transpl Infect Dis 2012; 14: 510-8.
31. Roblot F, Godet C, Le Moal G et al. Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients. Eur J Clin Microbiol Infect Dis 2002; 21: 523-31.
32. Brown GR. Cotrimoxazole-optimal dosing in the critically ill. Ann Intensive Care 2014; 4: 13.
33. Dao BD, Barreto JN, Wolf RC et al. Serum peak sulfamethoxazole concentrations demonstrate difficulty in achieving a target range: a retrospective cohort study. Curr Ther Res Clin Exp 2014; 76: 104-9.
34. Chin TW, Vandenbroucke A, Fong IW. Pharmacokinetics of trimethoprim-sulfamethoxazole in critically ill and non-critically ill AIDS patients. Antimicrob Agents Chemother 1995; 39: 28-33.
35. Safrin S, Finkelstein DM, Feinberg J et al. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized, trial of oral trimethoprimsulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. ACTG 108 Study Group. Ann Intern Med 1996; 124: 792-802.
36. Carmona EM, Limper AH. Update on the diagnosis and treatment of Pneumocystis pneumonia. Ther Adv Respir Dis 2011; 5: 41-59.
37. Cooley L, Dendle C, Wolf J et al. Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014. Intern Med J 2014; 44: 1350-63.
38. Vogel MN, Vatlach M, Weissgerber P et al. HRCT-features of Pneumocystis jiroveci pneumonia and their evolution before and after treatment in non-HIV immunocompromised patients. Eur J Radiol 2012; 81: 1315-20.
39. Held J, Wagner D. b-D-Glucan kinetics for the assessment of treatment response in Pneumocystis jirovecii pneumonia. Clin Microbiol Infect 2011; 17: 1118-22.
40. Lemiale V, Debrumetz A, Delannoy A et al. Adjunctive steroid in HIV-negative patients with severe Pneumocystis pneumonia. Respir Res 2013; 14: 87.
41. Nahimana A, Rabodonirina M, Zanetti G et al. Association between a specific Pneumocystis jiroveci dihydropteroate synthase mutation and failure of pyrimethamine/sulfadoxine prophylaxis in human immunodeficiency virus-positive and -negative patients. J Infect Dis 2003; 188: 1017-23.
42. Navin TR, Beard CB, Huang L et al. Effect of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of P. carinii pneumonia in patients with HIV-1: a prospective study. Lancet 2001; 358: 545-9.
43. Yoon C, Subramanian A, Chi A et al. Dihydropteroate synthase mutations in Pneumocystis pneumonia: impact of applying different definitions of prophylaxis, mortality endpoints and mutant in a single cohort. Med Mycol 2013; 51: 568-75.
44. Kim T, Kim SH, Park KH et al. Clindamycin-primaquine versus pentamidine for the second-line treatment of pneumocystis pneumonia. J Infect Chemother 2009; 15: 343-6.
45. KimT, HongHL, Lee YMet al. Is caspofungin really an effective treatment for Pneumocystis jirovecii pneumonia in immunocompromised patients without human immunodeficiency virus infection? Experiences at a single center and a literature review. Scand J Infect Dis 2013; 45: 484-8.
46. Helweg-Larsen J, Benfield T, Atzori C et al. Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study. J Antimicrob Chemother 2009; 64: 1282-90.
47. Armstrong-James D, Stebbing J, John L et al. A trial of caspofungin salvage treatment in PCP pneumonia. Thorax 2011; 66: 537-8.
48. Tu GW, Ju MJ, Xu M et al. Combination of caspofungin and low-dose trimethoprim/sulfamethoxazole for the treatment of severe Pneumocystis jirovecii pneumonia in renal transplant recipients. Nephrology (Carlton) 2013; 18: 736-42.
49. Utili R, Durante-Mangoni E, Basilico C et al. Efficacy of caspofungin addition to trimethoprim-sulfamethoxazole treatment for severe Pneumocystis pneumonia in solid organ transplant recipients. Transplantation 2007; 84: 685-8.
50. Lobo ML, Esteves F, de Sousa B et al. Therapeutic potential of caspofungin combined with trimethoprim-sulfamethoxazole for pneumocystis pneumonia: a pilot study in mice. PLoS One 2013; 8: e70619.
51. Kamboj M, Weinstock D, Sepkowitz KA. Progression of Pneumocystis jiroveci pneumonia in patients receiving echinocandin therapy. Clin Infect Dis 2006; 43: e92-4.
52. Azoulay E, Mokart D, Pene F et al. Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium-a groupe de recherche respiratoire en reanimation oncohematologique study. J Clin Oncol 2013; 31: 2810-8.
53. Azoulay E, Pène F, Darmon M et al. Managing critically ill hematology patients: Time to think differently. Blood Rev 2015; 29: 359-67.
54. Schellongowski P, Staudinger T, Kundi M et al. Prognostic factors for intensive care unit admission, intensive care outcome, and post-intensive care survival in patients with de novo acutemyeloid leukemia: a single center experience. Haematologica 2011; 96: 231-7.
55. Wohlfarth P, CarlströmA, Staudinger Tet al. Incidence of intensive care unit admission, outcome, and post intensive care survival in patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2016 Jan 13 [Epub ahead of print].
56. Roblot F, Le Moal G, Godet C et al. Pneumocystis carinii pneumonia in patients with hematologic malignancies: a descriptive study. J Infect 2003; 47: 19-27.
57. Mikaelsson L, Jacobsson G, Andersson R. Pneumocystis pneumonia-a retrospective study 1991-2001 in Gothenburg, Sweden. J Infect 2006; 53: 260-5.
58. Monnet X, Vidal-Petiot E, Osman D et al. Care management and outcome of severe Pneumocystis pneumonia in patients with and without HIV infection. Crit Care 2008; 12: R28.
59. Nüesch R, Bellini C, Zimmerli W. Pneumocystis carinii pneumonia in human immunodeficiency virus (HIV)-positive and HIV-negative immunocompromised patients. Clin Infect Dis 1999; 29: 1519-23.
60. Azoulay E, Lemiale V, Mokart D et al. Acute respiratory distress syndrome in patients with malignancies. Intensive Care Med 2014; 40: 1106-14.
61. Chaoui D, Legrand O, Roche N et al. Incidence and prognostic value of respiratory events in acute leukemia. Leukemia 2004; 18: 670-5.
62. Gruson D, Vargas F, Hilbert G et al. Predictive factors of intensive care unit admission in patients with haematological malignancies and pneumonia. Intensive Care Med 2004; 30: 965-71.
63. LenglinéE, Raffoux E, Lemiale V et al. Intensive care unit management of patients with newly diagnosed acute myeloid leukemia with no organ failure. Leuk Lymphoma 2012; 53: 1352-9.
64. Mokart D, Lambert J, Schnell D et al. Delayed intensive care unit admission is associated with increased mortality in patients with cancer with acute respiratory failure. Leuk Lymphoma 2013; 54: 1724-9.
65. Hilbert G, Gruson D, Vargas F et al. Noninvasive ventilation in immunosuppressed patients with pulmonary infiltrates, fever, and acute respiratory failure. N Engl J Med 2001; 344: 481-7.
66. Amado-Rodríguez L, Bernal T, López-Alonso I et al. Impact of initial ventilatory strategy in hematological patients with acute respiratory failure: a systematic review and meta-analysis. Crit Care Med 2016 Feb 23 [Epub ahead of print].
67. Lemiale V, Resche-Rigon M, Mokart D et al. Acute respiratory failure in patients with hematological malignancies: outcomes according to initial ventilation strategy. A groupe de recherche respiratoire en reánimation onco-hématologique (Grrr-OH) study. Ann Intensive Care 2015; 5: 28.
68. Lemiale V, Mokart D, Resche-Rigon M et al. Effect of noninvasive ventilation vs oxygen therapy on mortality among immunocompromised patients with acute respiratory failure: a randomized clinical trial. JAMA 2015; 314: 1711-9.
69. Adda M, Coquet I, Darmon M et al. Predictors of noninvasive ventilation failure in patients with hematologic malignancy and acute respiratory failure. Crit Care Med 2008; 36: 2766-72.
70. Depuydt PO, Benoit DD, Vandewoude KH et al. Outcome in noninvasively and invasively ventilated hematologic patients with acute respiratory failure. Chest 2004; 126: 1299-306.
71. Molina R, Bernal T, Borges M et al. Ventilatory support in critically ill hematology patients with respiratory failure. Crit Care 2012; 16: R133.
72. Soares M, Salluh JI, Azoulay E. Noninvasive ventilation in patients with malignancies and hypoxemic acute respiratory failure: a still pending question. J Crit Care 2010; 25: 37-8.
73. Ewald H, Raatz H, Boscacci R et al. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection. Cochrane Database Syst Rev 2015; 4: CD006150.
74. Limper AH, Knox KS, Sarosi GA et al. An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med 2011; 183: 96-128.
75. Roembke F, Heinzow HS, Gosseling T et al. Clinical outcome and predictors of survival in patients with Pneumocystis jirovecii pneumonia-results of a tertiary referral centre. Clin Respir J 2014; 8: 86-92.
76. Annaloro C, Della Volpe A, Usardi P et al. Caspofungin treatment of Pneumocystis pneumonia during conditioning for bone marrow transplantation. Eur J Clin Microbiol Infect Dis 2006; 25: 52-4.
77. Hof H, Schnülle P. Pneumocystis jiroveci pneumonia in a patient with Wegener's granulomatosis treated efficiently with caspofungin. Mycoses 2008; 51 Suppl 1: 65-7.
78. Burke BA, Good RA. Pneumocystis carinii infection. Medicine (Baltimore) 1973; 52: 23-51.
79. Delclaux C, Zahar JR, Amraoui G et al. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in non-human immunodeficiency virus-infected patients: retrospective study of 31 patients. Clin Infect Dis 1999; 29: 670-2.
80. Overgaard UM, Helweg-Larsen J. Pneumocystis jiroveci pneumonia (PCP) in HIV-1-negative patients: a retrospective study 2002-2004. Scand J Infect Dis 2007; 39: 589-95.
81. Pareja JG, Garland R, Koziel H. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest 1998; 113: 1215-24.
82. Zahar JR, Robin M, Azoulay E et al. Pneumocystis carinii pneumonia in critically ill patients with malignancy: a descriptive study. Clin Infect Dis 2002; 35: 929-34.